Profile of Multi Drug Resistant Tuberculosis patients: A Study at Drug Resistant Tuberculosis Centre in Kumaun Region, Uttarakhand

Published

2020-12-31

DOI:

https://doi.org/10.47203/IJCH.2020.v32i04.007

Keywords:

Drug Resistant Tuberculosis (DR-TB) Centre, Multi Drug Resistant Tuberculosis (MDR-TB)

Dimensions Badge

Issue

Section

Original Article

Authors

  • Sadhana Awasthi Government Medical College, Haldwani https://orcid.org/0000-0001-8468-4267
  • Neha Verma All India Institute of Medical Sciences, Rishikesh
  • Ram Gopal Nautiyal S.S.J. Government Institute of Med.S.J. Government Institute of Medical Sciences & Research, Almoraical Sciences & Research, Almora https://orcid.org/0000-0002-2820-6620
  • Hariom Kumar Solanki Government Institute of Medical Sciences, Greater Noida, GB Nagar https://orcid.org/0000-0002-2249-0149

Abstract

Background: Drug Resistant Tuberculosis (DR-TB) has frequently been encountered in India, and its presence has been known virtually from the time anti-TB drugs were introduced for the treatment of Tuberculosis. Multi Drug Resistant Tuberculosis (MDR-TB) is a man-made phenomenon and has become a formidable challenge to effective Tuberculosis control in India. Objectives: To study the Socio-demographic and Clinical profile of Multi Drug Resistant Tuberculosis (MDR-TB) patients presenting to Drug Resistant Tuberculosis (DR-TB) Centre at Govt. Medical College, Haldwani in the Kumaun region, Uttarakhand. Methodology:  This study is a Record based study, where in service data available at Drug Resistant Tuberculosis (DR-TB) Centre at Govt. Medical College, Haldwani in the Kumaun region, Uttarakhand, was accessed and analyzed. Inclusion criteria included all patients with diagnosis of Multi Drug Resistant Tuberculosis (MDR-TB) presenting to the centre from 1st April 2015 to 31st December 2015. Results: The present study showed that younger age group particularly males were more affected with MDR-TB. Under-nutrition was quite prevalent among the MDR-TB patients. 56.7% cases were addicted to alcohol and 54.3% cases were addicted to smoking. 85.8% patients took treatment for TB and 44.1% not completed their treatment. Relapse of previous anti-tuberculosis treatment was found to be the major contributor in MDR-TB suspect cases. Prevalence of XDR-TB was also found to be low. Conclusion: The findings of the study emphasize the importance of studying the socio-demographic factors and baseline clinical characteristics in different MDR-TB patient categories to timely modify and strengthen the national programs.

How to Cite

1.
Awasthi S, Verma N, Gopal Nautiyal R, Kumar Solanki H. Profile of Multi Drug Resistant Tuberculosis patients: A Study at Drug Resistant Tuberculosis Centre in Kumaun Region, Uttarakhand. Indian J Community Health [Internet]. 2020 Dec. 31 [cited 2022 Oct. 4];32(4):647-52. Available from: https://iapsmupuk.org/journal/index.php/IJCH/article/view/1728

Downloads

Download data is not yet available.

References

Barberis I, Bragazzi NL, Galluzzo L, Martini M. The history of tuberculosis: from the first historical records to the isolation of Koch's bacillus. J Prev Med Hyg. 2017;58(1):E9-E12. PMID: 28515626; PMCID: PMC5432783.[PubMed].

Alexander PE, De P. The emergence of extensively drug-resistant tuberculosis (TB): TB/HIV coinfection, multidrug-resistant TB and the resulting public healththreat from extensively drug-resistant TB, globally and in Canada. Can J Infect Dis Med Microbiol. 2007;18(5):289-91. doi: 10.11552007/986794. PMID: 1893728; PMCID: PMC2533560.[PubMed].

Drug-resistant tuberculosis - WHO. [Cited on 2020 Dec 4]. Available from: https://www.who.int/tb/areas-of-work/drug-resistant-tb/en/

Global tuberculosis report 2019 - WHO. [Cited on 2020 Dec 8]. Available from: https://www.who.int/tb/publications/global_report/en/

Drug-resistant TB: XDR-TB FAQ - WHO. [Cited on 2020 Dec 12]. Available from: https://www.who.int/tb/areas-of-work/drug-resistant-tb/xdr-tb-faq/en/

Sharma SK, Mohan A, Kadhiravan T. HIV-TB co-infection: epidemiology, diagnosis & management. Indian J Med Res. 2005 Apr;121(4):550-67. PMID: 15817963.[PubMed]

TB Alliance - Envisioning a world without TB·[Cited on 2020 Dec 22]. Available from: www.tballiance.org/

Prasad R, Singh A, Balasubramanian V, Gupta N. Extensively drug-resistanttuberculosis in India: Current evidence on diagnosis & management. Indian J MedRes. 2017;145(3):271-293. doi: 10.4103/ijmr.IJMR_177_16. PMID: 28749390; PMCID: PMC5555056.[PubMed].

Central TB Division, Directorate General of Health Services, Ministry of Health and Family Welfare. Guidelines on programmatic management of drug resistant tuberculosis (PMDT) in India. NirmanBhavan, New Delhi: Revised National Tuberculosis Control Programme; 2012:18-29.

Paramasivan CN, Venkataraman P. Drug resistance in tuberculosis in India. Indian J Med Res. 2004 Oct;120(4):377-86. PMID: 15520487.[PubMed]

Ramachandran R, Nalini S, Chandrasekar V, Dave PV, Sanghvi AS, Wares F, Paramasivan CN, Narayanan PR, Sahu S, Parmar M, Chadha S, Dewan P, Chauhan LS. Surveillance of drug-resistant tuberculosis in the state of Gujarat, India. IntJ Tuberc Lung Dis. 2009;13(9):1154-60. PMID: 19723407.[PubMed].

Paramasivan CN, Rehman F, Wares F, Sundar Mohan N, Sundar S, Devi S, Narayanan PR. First- and second-line drug resistance patterns among previously treated tuberculosis patients in India. Int J Tuberc Lung Dis. 2010;14(2):243-6. PMID: 20074419.[PubMed].

Datta BS, Hassan G, Kadri SM, Qureshi W, Kamili MA, Singh H, Manzoor A, Wani MA, Shamas-u-Din, Thakur N. Multidrug-resistant and extensively drug resistant tuberculosis in Kashmir, India. J Infect Dev Ctries. 2009 Nov 21;4(1):19-23. doi: 10.3855/jidc.669. PMID: 20130374.[PubMed].

Udwadia ZF, Moharil G. Multidrug-resistant-tuberculosis treatment in the Indian private sector: Results from a tertiary referral private hospital in Mumbai. Lung India. 2014;31(4):336-41. doi: 10.4103/0970-2113.142101. PMID:25378840; PMCID: PMC4220314.[PubMed].

Dholakia YN, Shah DP. Clinical profile and treatment outcomes of drug- resistant tuberculosis before directly observed treatment strategy plus: Lessons for the program. Lung India. 2013;30(4):316-20. doi: 10.4103/0970-2113.120608. PMID: 24339490; PMCID: PMC3841689.[PubMed].

Sharma SK, Kumar S, Saha PK, George N, Arora SK, Gupta D, Singh U, Hanif M, Vashisht RP. Prevalence of multidrug-resistant tuberculosis among category IIpulmonary tuberculosis patients. Indian J Med Res. 2011 Mar;133(3):312-5. PMID: 21441686; PMCID: PMC3103157.[PubMed].

Gupta S, Bandyopadhyay D, Gupta S, Sadhukhan S, Banerjees S. A sociodemographic study of multidrug resistant tuberculosis cases from DOTS clinics of Kolkata. J Indian Med Assoc. 2012;110(10):723-5. PMID: 23738405.[PubMed].

Mukherjee P, Prasanta Ray Karmakar P R, et al. Sociodemographic and clinical profile of multi drug resistant tuberculosis patients: a study at drug resistant tuberculosis centers of Kolkata. IOSR- J Dent Med Sci 2015; 14(8):52-8

Azhar GS. DOTS for TB relapse in India: A systematic review. Lung India. 2012;29(2):147-53. doi: 10.4103/0970-2113.95320. PMID: 22628930; PMCID: PMC3354489.[PubMed].

Sethi S, Mewara A, Dhatwalia SK, et al. Prevalence of multidrug resistance in Mycobacterium tuberculosis isolates from HIV seropositive and seronegative patients with pulmonary tuberculosis in north India.BMC Infectious Diseases.2013; 13:137. doi: 10.1186/1471-2334-13-137.

Sharma SK, Mohan A, Kadhiravan T. HIV-TB co-infection: epidemiology, diagnosis & management. Indian J Med Res. 2005;121(4):550-67. PMID: 15817963.[PubMed].

World Health Organization. TB/HIV: a clinical manual. Available from: http://whqlibdoc.who.int/publicatio ns/2004/9241546344.pdf

Sungkanuparph S, Eampokalap B, Chottanapund S, Thongyen S, Manosuthi W. Impact of drug-resistant tuberculosis on the survival of HIV-infected patients. Int J Tuberc Lung Dis. 2007;11(3):325-30. PMID: 17352100.[PubMed].

World Health Organization. Global tuberculosis report 2014. [Internet] [cited 2015 May 27 ]. Available from: http://apps.who.int/iris/bitstream/10665/137094/1/9789241564809_eng.pdf

Porwal C, Kaushik A, Makkar N, Banavaliker JN, Hanif M, Singla R, Bhatnagar AK, Behera D, Pande JN, Singh UB. Incidence and risk factors for extensively drug-resistant tuberculosis in Delhi region. PLoS One. 2013;8(2):e55299. doi: 10.1371/journal.pone.0055299. Epub 2013 Feb 4. PMI: 23390524; PMCID: PMC3563594.[PubMed]

Most read articles by the same author(s)